Compare NUVL & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | KNX |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.0B |
| IPO Year | 2021 | 1994 |
| Metric | NUVL | KNX |
|---|---|---|
| Price | $109.56 | $51.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | ★ $134.29 | $53.65 |
| AVG Volume (30 Days) | 756.3K | ★ 2.9M |
| Earning Date | 10-30-2025 | 01-21-2026 |
| Dividend Yield | N/A | ★ 1.40% |
| EPS Growth | N/A | ★ 280.63 |
| EPS | N/A | ★ 0.88 |
| Revenue | N/A | ★ $7,477,640,000.00 |
| Revenue This Year | N/A | $2.37 |
| Revenue Next Year | N/A | $5.55 |
| P/E Ratio | ★ N/A | $58.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.54 | $36.69 |
| 52 Week High | $112.88 | $61.51 |
| Indicator | NUVL | KNX |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 73.47 |
| Support Level | $103.51 | $45.64 |
| Resistance Level | $112.11 | $44.72 |
| Average True Range (ATR) | 5.16 | 1.48 |
| MACD | -0.24 | 0.83 |
| Stochastic Oscillator | 83.81 | 94.09 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.